Leadership Overview
Alvogen has 4 executives leading key functions including financial strategy, regional financial oversight, supply chain management, and marketing operations.
Focused on delivering high-quality generic pharmaceuticals, Alvogen maintains a commitment to global health accessibility through rigorous manufacturing standards and strategic market expansion across diverse international territories.
Focused on delivering high-quality generic pharmaceuticals, Alvogen maintains a commitment to global health accessibility through rigorous manufacturing standards and strategic market expansion across diverse international territories.
Leadership Roles at Alvogen
Greg Jester - Chief Financial Officer
Greg Jester, the Chief Financial Officer at Alvogen, directs all corporate fiscal planning and capital allocation strategies. Overseeing the financial health of the organization, the Chief Financial Officer ensures precise reporting and regulatory compliance across all pharmaceutical manufacturing divisions. This leadership role involves managing complex budgetary frameworks to support the development and marketing of generic drugs. By optimizing capital structures, Greg Jester directly impacts the long-term profitability and operational stability of the company. Jester monitors global market trends to mitigate financial risks while identifying opportunities for sustainable growth. Through rigorous analysis of revenue streams and cost management, the Chief Financial Officer maintains the fiscal integrity required to sustain competitive advantages in the pharmaceutical sector. Jester provides the board with critical insights regarding investment performance and liquidity management, ensuring the company remains well-positioned for future expansion and continued innovation in the global healthcare market.
Shekar Poojari - Chief Financial Officer, Alvogen Korea
Shekar Poojari, the Chief Financial Officer, Alvogen Korea at Alvogen, directs all financial operations within the East Asian market. Overseeing regional fiscal performance, the Chief Financial Officer, Alvogen Korea ensures alignment with corporate accounting standards while navigating local regulatory environments. This leadership role involves managing regional cash flow, tax planning, and investment strategies specific to the Korean pharmaceutical landscape. By streamlining financial processes, Shekar Poojari directly impacts the efficiency of regional manufacturing and distribution networks. Poojari coordinates with global leadership to integrate regional financial data into the broader corporate strategy. Through meticulous oversight of regional assets and liabilities, the Chief Financial Officer, Alvogen Korea secures the financial foundation necessary for market penetration and growth. Poojari drives initiatives to improve regional margins, ensuring that local operations contribute effectively to the overall success of the company while maintaining strict adherence to international financial reporting requirements.
Junseok Lim - Chief Marketing Officer, Scm & Sourcing & Manager
Junseok Lim, the Chief Marketing Officer, Scm & Sourcing & Manager at Alvogen, directs the integration of supply chain logistics with market demand strategies. Overseeing global sourcing initiatives, the Chief Marketing Officer, Scm & Sourcing & Manager ensures the consistent availability of raw materials for generic drug production. This leadership role involves managing vendor relationships and optimizing procurement cycles to reduce lead times. By aligning sourcing capabilities with marketing objectives, Junseok Lim directly impacts the company's ability to meet international demand for pharmaceutical products. Lim coordinates with manufacturing teams to ensure that supply chain efficiency supports the broader commercial goals of the organization. Through strategic oversight of logistics and inventory management, the Chief Marketing Officer, Scm & Sourcing & Manager maintains the operational agility required to respond to market fluctuations. Lim drives cost-reduction programs within the supply chain, ensuring that the company remains competitive while delivering essential medications to global markets.
Nilesh Bhanage - Director - Chief Marketing Officer Management
Nilesh Bhanage, the Director - Chief Marketing Officer Management at Alvogen, directs the administrative and strategic support functions for the marketing division. Overseeing the execution of commercial campaigns, the Director - Chief Marketing Officer Management ensures that marketing initiatives align with the company's portfolio of generic and parallel imported drugs. This leadership role involves coordinating cross-functional teams to enhance brand visibility and market penetration across diverse global regions. By refining internal management processes, Nilesh Bhanage directly impacts the productivity and output of the marketing department. Bhanage facilitates communication between executive leadership and marketing staff to ensure consistent messaging and strategic focus. Through the implementation of performance metrics and data-driven analysis, the Director - Chief Marketing Officer Management optimizes promotional activities to maximize return on investment. Bhanage supports the development of long-term commercial strategies, ensuring that the company effectively communicates the value of its pharmaceutical offerings to healthcare providers and patients worldwide.
Explore Leadership Teams in Manufacturing
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in neuroscience, biologics, and gene-based therapies.
Company Leadership

DQ
WC
Moderna is recognized as a pioneer in mRNA medicine, reshaping the way treatments and vaccines are created and delivered. By blending scientific innovation with advanced technology, the company continues to transform how society prevents and addresses disease across infectious conditions, cancer, rare disorders and autoimmune challenges. Guided by a distinctive culture and a global team committed to improving human health, Moderna focuses on developing mRNA-based medicines that can make a meaningful and lasting impact.
Company Leadership SI
KK
SI
RM
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. It markets to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company is headquartered in Parsippany, New Jersey.
Company Leadership LP
RV
SA
MT
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. PPS also offers development and manufacturing services for biologics including vaccines, gene therapies, and monoclonal antibodies, made possible through Piramal Pharma Limited's investment in Yapan Bio Private Limited. Our track record as a trusted service provider with experience across varied technologies we believe makes us a partner of choice for innovator and generic companies worldwide.
Company Leadership BC
SL

RM